Notice NOT-EB-19-006 from the NIH Guide for Grants and Contracts

Notice NOT-EB-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-AA-19-014 from the NIH Guide for Grants and Contracts

Competitive salary + Pension, Health insurance, Gym, bonus and many more benefits: Illumina: We currently have a fantastic opportunity for a Bioinformatics Algorithm Developer with either C or C++ to join our team. Great Abington, Cambridge

Notice NOT-NS-19-044 from the NIH Guide for Grants and Contracts

Notice NOT-NS-19-037 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-19-015 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). This FOA seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (UG3 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (UH3 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this FOA must address objectives for both the UG3 and UH3 phases and are expected to have a substantial collaborative effort between independents laboratories. This FOA is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED).

Next-Generation sequencing, bioinformatics, molecular genetics. The staff scientist trains technical staff, students, fellows and physicians in laboratory...
From Children's National Medical Center - Tue, 05 Mar 2019 19:32:16 GMT - View all Columbia, WA jobs

Salary in region of £17,489 per annum plus benefits: Wellcome Sanger Institute: Job Reference 83388 Bioinformatics Apprentice - IT (4 years) Salary in region of £17,489 per annum plus benefits Apprentice FTC 4 Years  We are Hinxton, Cambridgeshire, England

£30000 - £35000 per annum: Hyper Recruitment Solutions (HRS): We are currently looking for a Development Scientist to join a leading Biopharmaceutical company based in the Stevenage area. As the Development Scientist you will... Stevenage

Notice NOT-EY-19-019 from the NIH Guide for Grants and Contracts

Competitive Salary: PredictImmune Ltd: PredictImmune was created in early 2017 as a spin-out from the Department of Medicine, University of Cambridge... Babraham, Cambridge

Notice NOT-HG-19-017 from the NIH Guide for Grants and Contracts

Notice NOT-AG-19-007 from the NIH Guide for Grants and Contracts

Notice NOT-CA-19-028 from the NIH Guide for Grants and Contracts

Notice NOT-HS-19-012 from the NIH Guide for Grants and Contracts

Notice NOT-HD-19-005 from the NIH Guide for Grants and Contracts

Notice NOT-FD-19-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAS-19-210 from the NIH Guide for Grants and Contracts. This purpose of this FOA is to identify risk factors for dementia progression in PDD. Applicants must have access to well-characterized populations of PDD patients that have been followed longitudinally that they can continue to follow with clinical assessments and biospecimen collection until autopsy. Research should propose to identify clinical, pathological and/or biospecimen factors that predict which patients will develop cognitive impairment and/or dementia.

Funding Opportunity RFA-AI-19-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to establish a coordinated network of Emerging Infectious Disease Research Centers (EIDRCs) in regions around the globe where emerging and re-emerging infectious disease outbreaks are likely to occur. Multidisciplinary teams of investigators will conduct pathogen/host surveillance, study pathogen transmission, pathogenesis and immunologic responses in the host, and will develop reagents and diagnostic assays for improved detection for important emerging pathogens and their vectors.